<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154136</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-18</org_study_id>
    <nct_id>NCT05154136</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Open-Label, 2-period Drug-Drug Interaction Study to Investigate the Effect of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetic Profile of AB928 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of multiple oral doses of itraconazole, on the&#xD;
      pharmacokinetics of etrumadenant when etrumadenant is administered as a single dose in&#xD;
      healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Actual">November 23, 2021</completion_date>
  <primary_completion_date type="Actual">November 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study consists of 2 periods with participants sequentially receiving Treatment A (etrumadenant) in Period 1, followed by Treatment B (etrumadenant + itraconazole) in Period 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to Last Observed Non-zero Concentration [AUC(0-t)] of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time '0' Extrapolated to Infinity [AUC(0-inf)] of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC(0-inf) Extrapolation (AUC%extrap) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Plasma Clearance (CL/F) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent First-order Terminal Elimination Rate Constant (Kel) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent First Order Terminal Elimination Half-life (t1/2) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Etrumadenant Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf) of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC%extrap of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of Etrumadenant Metabolites When Etrumadenant is Administered With or Without Itraconazole</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose at Days 1, 2, 3, 4, 5, and 6 during Period 1; and Days 5, 6, 7, 9, and 11 during Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Safety will be assessed by monitoring adverse events and clinically significant changes in 12 lead Electrocardiogram, vital signs, and clinical laboratory tests results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Etrumadenant then Etrumadenant + Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).&#xD;
A washout period of 5 days will be maintained between the two treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrumadenant</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Etrumadenant then Etrumadenant + Itraconazole</arm_group_label>
    <other_name>AB928</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Etrumadenant then Etrumadenant + Itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, male or female (of non-childbearing potential), at the screening visit&#xD;
&#xD;
          -  Body mass index between 18 and 32 kilograms/m^2 inclusive, at screening&#xD;
&#xD;
          -  Healthy as determined by pre-study medical history, physical examination, vital signs,&#xD;
             complete neurological examination and 12-lead ECG&#xD;
&#xD;
          -  Clinical laboratory test results clinically acceptable at screening and check-in&#xD;
&#xD;
          -  Non-smokers or ex-smokers (must have ceased smoking and stopped using nicotine&#xD;
             containing products &gt;3 months prior to the first dosing) based on participant&#xD;
             self-reporting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have a clinically relevant history or presence of respiratory,&#xD;
             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,&#xD;
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,&#xD;
             dermatological, rheumatological, endocrine, connective tissue diseases or disorders&#xD;
&#xD;
          -  Have a clinically relevant surgical history in the opinion of the principal&#xD;
             investigator or designee&#xD;
&#xD;
          -  Have a history of relevant atopy or hypersensitivity to the study drugs or related&#xD;
             compounds (e.g., allergy to itraconazole or other azole antifungals&#xD;
&#xD;
          -  History or presence of alcohol or drug abuse within the past 2 years prior to the&#xD;
             first dosing&#xD;
&#xD;
        Note: This is not an exhaustive list of criterias.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etrumadenant</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Healthy participants</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <keyword>AB928</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

